Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 60mg

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 90mg

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga manufacturing berhad - daclatasvir dihydrochloride -

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - daclatasvir dihydrochloride -

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - daclatasvir dihydrochloride -

Union européenne - anglais - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitis c, chronic - antivirals for systemic use - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (see sections 4.2, 4.4 and 5.1).

Union européenne - anglais - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir - hepatitis c, chronic - antivirals for systemic use - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).

Tanzanie - anglais - Tanzania Medicinces & Medical Devices Authority

cadila healthcare limited, india - daclatasvir dihydrochloride - tablets - 30

Tanzanie - anglais - Tanzania Medicinces & Medical Devices Authority

cadila healthcare limited, india - daclatasvir dihydrochloride - tablets - 60

Tanzanie - anglais - Tanzania Medicinces & Medical Devices Authority

hetero laboratories limited, india - daclatasvir dihydrochloride - tablets - 30 mg